Mozobil is a mobilization agent for those who have been diagnosed with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM) and are expected to eventually undergo an autologous hematopoietic cell transplantation (autologous HCT).
As a person’s own cells will be used in autologous HCT, a transplant team must collect them prior to treatment for cancer and keep them until transplant. Mozobil helps to release stem cells from the bone marrow into the bloodstream so they can be collected for transplant through a process called stem cell mobilization.
Mozobil + G-CSF was found to significantly reduce mobilization failures vs G-CSF alone in two well-controlled trials evaluating safety and efficacy
Percentage of patients with MM who achieved the target stem cell collection goal* in 2 or fewer days of apheresis with Mozobil + G-CSF (n=148) vs placebo + G-CSF (n=154), respectively
Percentage of patients with NHL who achieved the target stem cell collection goal in 4 or fewer days of apheresis with Mozobil + G-CSF (n=150) vs placebo + G-CSF (n=148), respectively
*Target=6 million CD34+ cells/kg
Target=5 million CD34+ cells/kg
Significantly higher success rates for mobilizing stem cells was seen with Mozobil + G-CSF compared to placebo + G-CSF
Potential for fewer apheresis procedures
Talk to a doctor or healthcare provider about whether or not Mozobil should be taken while:
People who have leukemia should not receive Mozobil. Taking Mozobil to increase stem cells while you have leukemia may increase the number of leukemic cells in the bloodstream.
Mozobil can harm the unborn child when administered to a pregnant woman. If you are a female of childbearing potential you should use an effective form of contraception during treatment with Mozobil and for one week after the final dose. Breastfeeding is not recommended during treatment with Mozobil and for one week after the final dose.
Mozobil works by releasing stem cells from the bone marrow, making them available to collect from your bloodstream. Specifically, Mozobil binds to a protein on the surface of stem cells called CXCR4. Normally, these stem cells are present in the bloodstream in very low numbers since they are more likely to stay in the bone marrow. Mozobil increases the levels of stem cells in the blood by preventing them from remaining anchored inside the bone marrow space. This enables your healthcare team to collect more stem cells during apheresis.
Stem cells anchored in the bone marrow through the CXCR4/SDF-1α interaction
Mozobil disrupts the CXCR4/SDF-1α interaction
Stem cells moving into the bloodstream